Related Experiment Videos

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

Elizabeth Iorns1, Nicholas C Turner, Richard Elliott

  • 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.

Cancer Cell
|February 5, 2008
PubMed

Insights

CDK10 is a key factor in endocrine therapy resistance for estrogen receptor-positive breast cancer. Low CDK10 levels predict early relapse on tamoxifen, suggesting it as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Estrogen signaling therapies are vital for breast cancer treatment.
  • Therapy resistance remains a significant clinical challenge, limiting treatment efficacy.
  • Identifying resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To identify novel modifiers of tamoxifen sensitivity in breast cancer.
  • To investigate the role of CDK10 in endocrine therapy resistance.
  • To elucidate the molecular mechanisms underlying CDK10-mediated resistance.

Main Methods:

  • Conducted an RNA interference (RNAi) screen to identify genes modulating tamoxifen sensitivity.
  • Utilized molecular biology techniques to analyze gene transcription and pathway activation.
  • Correlated CDK10 expression levels with clinical data from patients with ER alpha-positive breast cancer.

Main Results:

  • CDK10 was identified as a critical determinant of resistance to endocrine therapies.
  • CDK10 silencing enhanced ETS2-driven transcription of c-RAF, activating the MAPK pathway.
  • Low CDK10 expression in ER alpha-positive tumors correlated with early relapse on tamoxifen.
  • Reduced CDK10 expression is associated with promoter methylation, suggesting a regulatory mechanism.

Conclusions:

  • CDK10 plays a significant role in mediating resistance to estrogen-targeting therapies in breast cancer.
  • The CDK10-ETS2-c-RAF-MAPK axis represents a novel pathway driving endocrine resistance.
  • CDK10 levels can serve as a predictive biomarker for tamoxifen response and a potential therapeutic target.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.